FDA OKs Combo Therapy for Aggressive Thyroid Cancer

FDA OKs Combo Therapy for Aggressive Thyroid Cancer


The U.S. Food and Drug Administration on Friday approved Novartis AG’s combination therapy to treat an aggressive type of thyroid cancer.

The therapy, which uses Novartis’ Tafinlar and Mekinist, was approved to treat anaplastic thyroid cancer that cannot be removed surgically or has spread to other parts of the body, and has a type of abnormal gene known as BRAF V600E.

This is the first FDA-approved treatment for patients with this form of thyroid cancer and the third type of cancer with this specific gene mutation, the FDA said > >> read more ...

Talk Therapy Helps Soldiers Combat Insomnia

Talk Therapy Helps Soldiers Combat Insomnia


Talk therapy for insomnia is effective at reducing insomnia, as well as mental fatigue, among military personnel, according to a new study.
For the new analysis, published online in Sleep, researchers recruited 151 active-duty U.S. Army personnel stationed at Fort Hood, Texas who had chronic insomnia and randomly assigned half of them to receive six weekly 60-minute sessions of a treatment cognitive behavior therapy for insomnia (CBTi).

All the soldiers had served at least one military deployment in or around Iraq or Afghanistan. The average age was about 32, and more than 80 percent were male. > >> read more ...

Golf Great Jack Nicklaus Has ‘Secret’ Stem Cell Therapy for Back Pain

Golf Great Jack Nicklaus Has ‘Secret’ Stem Cell Therapy for Back Pain


Golfing great Jack Nicklaus receives “secret” stem cell therapy to treat chronic back pain that marred much of his competitive professional career and continued long after, CNN reported.

The 78-year-old Golden Bear has been hailed as a legend for his five decades of golf, but during many of those years he had aggravating back pain, enough to force him to withdraw from some tournaments.

Nicklaus reportedly tried almost every therapy under the sun, including cortisol injections and a back operation. > >> read more ...

Study: Immune Therapy Scores Big Win Against Lung Cancer

Study: Immune Therapy Scores Big Win Against Lung Cancer


For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It’s the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.

In the study, Merck’s Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it’s found. > >> read more ...

Immune Therapy Boosts Lung Cancer Survival Rates, Study Finds

Immune Therapy Boosts Lung Cancer Survival Rates, Study Finds


Immune therapy improved lung cancer survival rates in a new study of those recently diagnosed with the disease in the biggest win so far for the treatment, which has had much of its success until now in less common cancers.

In the study, Merck’s Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year, according to The Associated Press. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it’s found. > >> read more ...

Immune Therapy Scores Big Win Against Lung Cancer in Study

Immune Therapy Scores Big Win Against Lung Cancer in Study


For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It’s the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.

In the study, Merck’s Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it’s found. > >> read more ...

Can Non-Drug Therapy Help With Memory Loss?

Can Non-Drug Therapy Help With Memory Loss?


You know the feeling: You’ve misplaced your keys for what seems to be the zillionth time, or forget the name of a friend you’ve known for years. Does this mean that you’re on the way to developing Alzheimer’s disease?

Not necessarily, experts say. What you’re experiencing may simply be a minor memory lapse tied to growing older, or mild cognitive impairment (MCI) — a common condition that may, or may not, progress to Alzheimer’s disease.

The good news is that a handful of non-drug treatments — including a therapy known as neurofeedback training — can help with memory lapses and MCI. > >> read more ...

Precision Cancer Therapy Works in 3/4 of Patients

Precision Cancer Therapy Works in 3/4 of Patients


A precision cancer treatment that targets rare genetic mutations that exist in about 5,000 people in the United States instead of the tumor’s location in the body has shown success in three-quarters of patients, researchers said Wednesday.

The medicine, called larotrectinib, is made by Loxo Oncology of Stamford, Connecticut and was granted breakthrough therapy designation by the US Food and Drug Administration in 2016.

Taken orally once or twice a day, it interferes with an on-switch for cancer growth caused by an acquired genetic defect, known as tropomyosin receptor kinase (TRK) fusions. > >> read more ...

FDA Opens New Avenue for Alzheimer’s Therapy

FDA Opens New Avenue for Alzheimer’s Therapy


U.S. drug regulators wants to let drugmakers test Alzheimer’s disease treatments on patients years before the disease shows outward signs, and could approve the therapies based on subtle biological signals rather than proof they alleviate symptoms.

The Food and Drug Administration proposal will open new paths for drugmakers after repeated failures from companies including Pfizer Inc., Eli Lilly & Co. and Merck & Co. It also poses a scientific challenge: Researchers don’t fully understand the biological progression of Alzheimer’s disease, leaving the industry without a clear finish line or target. > >> read more ...

New Therapy Targets Hard-to-Treat Prostate Cancer

New Therapy Targets Hard-to-Treat Prostate Cancer


The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson’s Erleada treatment for use in prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the regulator said. 

The approval was based on a trial goal that measured the length of time tumors did not spread to other parts of the body, or death occurred after starting the treatment, the FDA said. > >> read more ...